On Friday, the US stock market prepared for a downward opening, as evidenced by a notable decline in Dow futures. This pre-market dip was primarily driven by the poor performance of several major companies, with Zenas Biopharma and Daqo New Energy leading the list of those experiencing significant share price reductions.
Pre-Market Plunge: Zenas Biopharma and Daqo New Energy Lead Stock Declines
As the trading week drew to a close on Friday, March 27, 2026, the US stock market saw its futures indicating a bearish trend, with the Dow futures specifically registering a fall of around 100 points. This anticipated downturn was largely influenced by the performance of individual companies in the pre-market session. Notably, Zenas Biopharma Inc. (NASDAQ: ZBIO) witnessed a sharp decline of 9.5%, with its shares trading at $20.05. This dip followed the company's announcement of concurrent public offerings of 2.50% convertible senior notes due in 2032 and common stock, aiming to raise aggregate gross proceeds of $300.0 million. Meanwhile, Daqo New Energy Corp (NYSE: DQ) experienced an even steeper fall, plummeting by 20% to $17.00 per share, a reaction to the mixed quarterly results the company reported on Thursday. Other companies also faced losses, including Armata Pharmaceuticals Inc. (NYSE: ARMP), which dropped 9.1% after reporting a fourth-quarter loss, and Upstream Bio Inc. (NASDAQ: UPB), which saw an 8% decrease despite announcing a Phase 3 development strategy for its treatment. Lithium Argentina AG (NYSE: LAR) and Enlight Renewable Energy Ltd (NASDAQ: ENLT) also recorded declines of 6.8% and 6.6%, respectively, in a widespread pre-market slump.
This broad-based decline in pre-market trading serves as a crucial indicator for investors, highlighting the volatile nature of the stock market influenced by corporate financial news and broader economic sentiments. The performance of these leading stocks often sets the tone for the day's trading, emphasizing the importance of diligent market analysis for strategic investment decisions.